Breast Development in Transwomen After 1 Year of Cross-Sex Hormone Therapy: Results of a Prospective Multicenter Study

@article{deBlok2018BreastDI,
  title={Breast Development in Transwomen After 1 Year of Cross-Sex Hormone Therapy: Results of a Prospective Multicenter Study},
  author={Christel J M de Blok and M. Klaver and Chantal Maria Wiepjes and Nienke M Nota and Annemieke C. Heijboer and Alessandra D. Fisher and Thomas Gabriel Schreiner and Guy T’Sjoen and Martin den Heijer},
  journal={The Journal of Clinical Endocrinology \& Metabolism},
  year={2018},
  volume={103},
  pages={532–538}
}
Context Breast development is a key feature of feminization and therefore important to transwomen (male-to-female transgender persons. [] Key MethodDesign This study was performed as part of the European Network for the Investigation of Gender Incongruence, which is a prospective multicenter cohort study. Setting Gender clinics in Amsterdam, Ghent, and Florence. Participants Transwomen who completed the first year of CHT (n = 229). Intervention CHT.

Figures and Tables from this paper

Sustained breast development and breast anthropometric changes in three years gender-affirming hormone treatment.

Sustained breast growth and development during hormone treatment was observed during the full three-year observation period, and although modest breast volumes were observed, breast development was satisfactory to most trans women.

Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands

In trans women, the risk of breast cancer increased during a relatively short duration of hormone treatment and the characteristics of the breast cancer resembled a more female pattern, suggesting that breast cancer screening guidelines for cisgender people are sufficient for transgender people using hormone treatment.

Breast Cancer in Transgenders: Narrative Review

There are no international guidelines on screening and management of transgender patients but it appears that breast screening before cosmetic mastectomy, exposure to hormonal therapy for more than 5 years, and as per natal women screening guidelines should be offered to the patient with detailed discussion on the harms and benefits of the same.

The Breast Response to Estrogenic Stimulation in Transwomen Classification

The BREST scale uniquely captures the differences in breast phenotypes in transgender women according to hormone therapy response and provides a transwoman-specific metric allowing for a common language in assessment of transgender breast development and optimal communication among providers, different specialties, and insurance companies.

Safety and rapid efficacy of guideline-based gender affirming hormone therapy: an analysis of 388 individuals diagnosed with gender dysphoria.

Investigation in a large cohort of individuals under guideline-based treatment found gender affirming hormone therapy in accordance with current clinical-practice guidelines is efficient and safe.

Management of endocrine disease: Optimal feminizing hormone treatment in transgender people.

Evidence is discussed regarding established and upcoming feminizing treatment for adult transgender women or for gender non-binary people seeking feminization, with special focus on the pharmacotherapy of feminizing hormonal therapy.

Progesterone Is Important for Transgender Women’s Therapy—Applying Evidence for the Benefits of Progesterone in Ciswomen

  • J. Prior
  • Medicine, Biology
    The Journal of clinical endocrinology and metabolism
  • 2019
Accumulated evidence indicates that normally ovulatory menstrual cycles are necessary for ciswomen's current fertility, as well as for later-life bone and cardiovascular health and the prevention of breast and endometrial cancers, and transgender women deserve progesterone therapy and similar potential physiological benefits.

Cardiovascular Risk Associated With Gender Affirming Hormone Therapy in Transgender Population

This review examines the impact of GAHT in the transgender population on CV outcomes and surrogate markers of CV health and reviews available data on changes in DNA methylation or RNA transcription induced by GAHT that may translate into changes in metabolic parameters that could increase CV risk.

Mapping evidence on the effects of gender-affirming hormone therapy on the hard and soft tissues of the craniofacial complex in transgender people: a protocol for a scoping review

The aim of this scoping review is to systematically map the available evidence in order to provide an overview of the effects of GAH therapy on the hard and soft tissues of the craniofacial complex in transgender people.
...

References

SHOWING 1-10 OF 27 REFERENCES

Clinical review: Breast development in trans women receiving cross-sex hormones.

The available evidence suggests that breast development is insufficient for the majority of trans women and that type and dosage of hormonal therapy seem not to have an important role on final breast size.

Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens.

Self-medication with estrogen is significantly more likely to result in a later request for mammoplasty than is treatment prescribed by licensed practitioners and CEE treatment is associated with a higher incidence of thromboembolism than treatment with other estrogen types.

Cross-Sex Hormone Treatment and Psychobiological Changes in Transsexual Persons: Two-Year Follow-Up Data.

The efficacy of CHT intervention in improving subjective perception of one's own body, which was partially associated with objective changes, supports the efficacy ofCHT intervention on psychobiological well-being in GDs.

Physical and hormonal evaluation of transsexual patients: A longitudinal study

Based on the data generated by this study, it is recommended as hormonal therapy 0.1–0.5 mg/day of ethinyl estradiol or 7.5–10 mg/ day of conjugated estrogen for male-to-female transsexuals, and intramuscular testosterone cypionate, 200 mg every 2 weeks, for female- to-male transsexuals.

Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist.

It is concluded that cross-sex hormone treatment of male-to-female transsexuals using GnRHa and oestradiol-17beta valerate is effective, and side effects and complication rates can be reduced using the treatment regimen presented here.

Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism

The clinical and hormonal response to 12-month therapy with the antiandrogen, spironolactone, in conjunction with near-physiologic doses of female gonadal steroids in 50 transsexual males, is

Augmentation mammaplasty in male-to-female transsexuals.

The basic anatomic and surgical considerations of augmentation mammaplasty for 201 male-to-female transsexuals who were operated on from 1979 to 1997 are reviewed and discussed.

Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline.

This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence, which was low or very low.